SGLT2 inhibitors in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis

Abstract

Funding Acknowledgements Type of funding sources: None. Background Over the recent months, the scenery of the pharmacological treatment of heart failure has changed. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have become the protagonists, as trial after trial is revealing a prognostic benefit of their use for patients with heart failure (HF). While their clear advantage in heart failure with reduced ejection fraction (HFrEF) has resulted in the addition of SGLT2i in the most recent treatment guidelines 1, the magnitude of their impact in heart failure with preserved ejection fraction (HFpEF) is still debated. With the recent results of EMPEROR-Preserved trial shedding more light into this matter 2, concrete evidence is needed now more than ever to ascertain the role of SGLT2i in the management of HFpEF. Aims We performed a systematic review and meta-analysis to evaluate the role of SLGT2i in the management of patients with HF. More specifically, we performed a pre-specified subgroup analysis to assess the impact of this drug class in heart failure with reduced and preserved ejection fraction separately. Methods We conducted a systematic search of PubMed, Embase, Cochrane and Web of Science databases from inception to 15th of September. With the primary endpoint being hospitalisation for heart failure (HHF) or cardiovascular death (CVD), we identified 9,493 articles out of which 8 randomised controlled trials and 20,758 patients were included in the meta-analysis 2–9. The hazard ratios (HR) and 95% CI given in each study were used for the meta-analysis. A random-effects model with inverse-variance weights was used to combine the effect measures from all studies on a logarithmic scale. Statistical heterogeneity was assessed using the I² statistic. The statistical analyses were conducted using the Review Manager (RevMan) software (version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Results The use of SGLT2i was associated with a significant reduction in HHF or CVD both for the patients with heart failure and EF>40% (HR=0.78, 95%CI: 0.69, 0.87; I2 0%) and for the patients with heart failure and EF<40% (HR=0.74, 95%CI: 0.68, 0.81; I2 0%), while for the total population SGLT2i reduced the risk of HHF or CV death by 25% (HR=0.75, 95%CI: 0.70, 0.81; I2 0%) (figure 1). Additionally, a prespecified subanalysis showed that in the specific cohort of patients with heart failure and EF>50%, SGLT2i resulted in 23% lower risk of HHF or CV death (HR=0.77, 95%CI: 0.66, 0.91; I2 22%) (figure 2). Conclusion This meta-analysis provides robust evidence that SGLT2i appear to have a prognostic benefit across the spectrum of heart failure subgroups in terms of HHF or CV death. Further large-scale randomised trials examining the role of this drug class in the management of HFpEF would be extremely valuable and might transform the field of therapeutic strategies in this challenging clinical entity.

Covid-19 and post-acute sick leave: a hybrid register and questionnaire study in the adult Danish population

“…It has been estimated that 10-20% of people infected with SARS-CoV-2 develop long covid (2). With studies pointing to varying symptom clusters (3)(4)(5)(6), unclear pathogenesis (1,7), and a limited understanding of risk factors (8)(9)(10)(11), long covid remains enigmatic. In particular, it is still unclear how many previously infected suffer from long covid to such an extent that it is severely disruptive to daily living and quality of life, and in turn also disruptive to society (12).…”

Exploring risk factors for persistent neurocognitive sequelae after hospitalization for COVID‐19

“…Other studies have also found females to be significantly more likely to report persistent neurocognitive symptoms following SARS-CoV2 infection. 21,[31][32][33][34][35] One study suggests that discrepancies in sex hormones related to inflammatory processes may also contribute to this difference we see in COVID-19 response. 36 The expression of angiotensin-converting enzyme-2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) receptors, both of which are likely involved in COVID-19 pathogenesis, has also been suggested to differ between the sexes and may play a role in the long-term effects of COVID-19.…”

Rheumatology and Long COVID: lessons from the study of fibromyalgia

“…These same nociplastic pain mechanisms are also commonly superimposed on nociceptive pain states such as autoimmune disorders, where up one-third or more are thought to have what used to be called secondary FM and then more recently central sensitisation. The risk factors for these conditions include female sex (which has 1.5–2×OR), SES factors, poor sleep, physical inactivity and cigarette smoking, which overlaps a tremendous amount with what is seen in Long COVID 12 13. In the studies that have closely examined the postinfectious pain manifestations of both COVID and similar postinfectious syndromes, individuals who have pain preinfection are likely to be left with more chronic pain as one of the sequelae, although many develop de novo pain 14–17…”